Goldman SachsGSPAST TOP PICKMay 12, 2015Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
(A Top Pick May 9/14. Up 29.25%.) This is a huge power in underwriting and investment banking in the US. Have always had a terrific record of proprietary trading, also make some money in commercial lending. The climate for offerings in the US really good, so they are making a lot of money on that side. The volatility in the bond market is good for traders. They raised their dividend.